MedPath

The Acute, Synergistic Effects of Protein and Calcium on Appetite and Energy Intake

Not Applicable
Conditions
Healthy
Interventions
Dietary Supplement: Porridge-based breakfast.
Dietary Supplement: Protein
Dietary Supplement: Calcium
Registration Number
NCT01986036
Lead Sponsor
Northumbria University
Brief Summary

High-protein meals have previously been shown to acutely reduce appetite and energy intake. More recently, meals higher in calcium have also been shown to increase feelings of fullness, circulating insulin and intestinal peptide concentrations and reduce appetite sensations.

This study aims to assess whether calcium and protein act synergistically to acutely influence appetite and energy intake.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
20
Inclusion Criteria
  • Male or Female
  • BMI 18.5-29.9 kg/m2
  • Age: 18-40 years
Exclusion Criteria
  • Smokers
  • Food allergies
  • Metabolic disorders (ie. type 2 diabetes)

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
CONTROLPorridge-based breakfast.Control breakfast low in protein and calcium. Porridge-based breakfast.
PROTEINProteinHigh-protein breakfast.
PROTEINPorridge-based breakfast.High-protein breakfast.
CALCIUMCalciumHigh-calcium breakfast.
CALCIUMPorridge-based breakfast.High-calcium breakfast.
PRO-CALProteinHigh-protein and calcium breakfast.
PRO-CALCalciumHigh-protein and calcium breakfast.
PRO-CALPorridge-based breakfast.High-protein and calcium breakfast.
Primary Outcome Measures
NameTimeMethod
Energy Intake60 min post test-meal

Energy intake will be assessed by ad libitum consumption of a homogenous pasta meal, 1 h after the test-meal.

Secondary Outcome Measures
NameTimeMethod
Subjective appetite sensations1 hr

Subjective appetite sensations (hunger, satisfaction, prospective consumption and fullness) will be assessed by visual analogue scales at baseline, and every 15 min following test-meal consumption.

Insulin concentrations1 hr

Plasma insulin concentrations will be determined at baseline and every 15 min following test-meal consumption.

GLP-1 (7-36) concentrations1 hr

Plasma glucagon-like peptide-1 (GLP-1) (7-36) concentrations will be determined at baseline and every 15 min following consumption of the test meal.

GIP concentration1 hr

Plasma glucose-dependent insulinotropic peptide (GIP) concentrations will be determined at baseline and evert 15 min following test-meal consumption.

Trial Locations

Locations (1)

Northumbria University

🇬🇧

Newcastle upon Tyne, Tyne and Wear, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath